The University of Chicago Header Logo

Connection

George Bakris to Aged

Back to Details
This is a "connection" page, showing publications George Bakris has written about Aged.
George Bakris
Connection Strength
3.920
Aged
  1. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.070
  2. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S195-S207.
    View in: PubMed
    Score: 0.063
  3. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976.
    View in: PubMed
    Score: 0.063
  4. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
    View in: PubMed
    Score: 0.062
  5. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81.
    View in: PubMed
    Score: 0.060
  6. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
    View in: PubMed
    Score: 0.058
  7. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
    View in: PubMed
    Score: 0.056
  8. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.055
  9. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
    View in: PubMed
    Score: 0.054
  10. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808.
    View in: PubMed
    Score: 0.050
  11. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702.
    View in: PubMed
    Score: 0.048
  12. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499.
    View in: PubMed
    Score: 0.048
  13. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3.
    View in: PubMed
    Score: 0.047
  14. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345.
    View in: PubMed
    Score: 0.045
  15. Searching for the Optimal Blood Pressure Range in the Elderly: Are We There Yet? J Am Coll Cardiol. 2017 02 07; 69(5):494-496.
    View in: PubMed
    Score: 0.045
  16. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100.
    View in: PubMed
    Score: 0.044
  17. Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. J Clin Hypertens (Greenwich). 2016 12; 18(12):1216-1221.
    View in: PubMed
    Score: 0.043
  18. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12.
    View in: PubMed
    Score: 0.042
  19. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
    View in: PubMed
    Score: 0.041
  20. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
    View in: PubMed
    Score: 0.040
  21. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
    View in: PubMed
    Score: 0.040
  22. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
    View in: PubMed
    Score: 0.039
  23. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.039
  24. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
    View in: PubMed
    Score: 0.037
  25. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
    View in: PubMed
    Score: 0.037
  26. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701.
    View in: PubMed
    Score: 0.035
  27. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
    View in: PubMed
    Score: 0.034
  28. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9.
    View in: PubMed
    Score: 0.034
  29. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
    View in: PubMed
    Score: 0.033
  30. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10.
    View in: PubMed
    Score: 0.033
  31. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51.
    View in: PubMed
    Score: 0.033
  32. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
    View in: PubMed
    Score: 0.032
  33. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.031
  34. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
    View in: PubMed
    Score: 0.029
  35. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
    View in: PubMed
    Score: 0.029
  36. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
    View in: PubMed
    Score: 0.029
  37. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.028
  38. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.028
  39. Hypertension and its management in the elderly. Semin Nephrol. 2009 Nov; 29(6):604-9.
    View in: PubMed
    Score: 0.027
  40. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.027
  41. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3.
    View in: PubMed
    Score: 0.026
  42. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.026
  43. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
    View in: PubMed
    Score: 0.026
  44. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
    View in: PubMed
    Score: 0.024
  45. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
    View in: PubMed
    Score: 0.024
  46. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
    View in: PubMed
    Score: 0.024
  47. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.024
  48. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
    View in: PubMed
    Score: 0.024
  49. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.024
  50. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9.
    View in: PubMed
    Score: 0.024
  51. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
    View in: PubMed
    Score: 0.023
  52. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007 Sep; 21(9):709-16.
    View in: PubMed
    Score: 0.023
  53. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52.
    View in: PubMed
    Score: 0.022
  54. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.022
  55. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.022
  56. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
    View in: PubMed
    Score: 0.022
  57. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006 Oct 02; 98(7A):32L-38L.
    View in: PubMed
    Score: 0.022
  58. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
    View in: PubMed
    Score: 0.021
  59. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
    View in: PubMed
    Score: 0.020
  60. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol. 2005 Jul-Aug; 25(4):393-9.
    View in: PubMed
    Score: 0.020
  61. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.020
  62. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9.
    View in: PubMed
    Score: 0.020
  63. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.019
  64. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
    View in: PubMed
    Score: 0.019
  65. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
    View in: PubMed
    Score: 0.019
  66. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4.
    View in: PubMed
    Score: 0.019
  67. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.018
  68. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
    View in: PubMed
    Score: 0.018
  69. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
    View in: PubMed
    Score: 0.018
  70. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
    View in: PubMed
    Score: 0.017
  71. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
    View in: PubMed
    Score: 0.017
  72. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
    View in: PubMed
    Score: 0.017
  73. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.016
  74. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.016
  75. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
    View in: PubMed
    Score: 0.016
  76. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
    View in: PubMed
    Score: 0.016
  77. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447.
    View in: PubMed
    Score: 0.016
  78. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
    View in: PubMed
    Score: 0.016
  79. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
    View in: PubMed
    Score: 0.015
  80. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263.
    View in: PubMed
    Score: 0.015
  81. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152.
    View in: PubMed
    Score: 0.015
  82. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624.
    View in: PubMed
    Score: 0.015
  83. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
    View in: PubMed
    Score: 0.015
  84. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
    View in: PubMed
    Score: 0.015
  85. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21.
    View in: PubMed
    Score: 0.015
  86. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.
    View in: PubMed
    Score: 0.015
  87. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
    View in: PubMed
    Score: 0.015
  88. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910.
    View in: PubMed
    Score: 0.015
  89. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914.
    View in: PubMed
    Score: 0.014
  90. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
    View in: PubMed
    Score: 0.014
  91. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66.
    View in: PubMed
    Score: 0.014
  92. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
    View in: PubMed
    Score: 0.014
  93. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.
    View in: PubMed
    Score: 0.014
  94. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives". J Clin Pharmacol. 2000 Jan; 40(1):7-10.
    View in: PubMed
    Score: 0.014
  95. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
    View in: PubMed
    Score: 0.014
  96. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
    View in: PubMed
    Score: 0.014
  97. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
    View in: PubMed
    Score: 0.013
  98. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
    View in: PubMed
    Score: 0.013
  99. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
    View in: PubMed
    Score: 0.013
  100. Assessing kidneys that may be fragile. Postgrad Med. 1998 Nov; 104(5):31.
    View in: PubMed
    Score: 0.013
  101. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.
    View in: PubMed
    Score: 0.013
  102. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
    View in: PubMed
    Score: 0.013
  103. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.013
  104. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
    View in: PubMed
    Score: 0.012
  105. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505.
    View in: PubMed
    Score: 0.012
  106. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
    View in: PubMed
    Score: 0.012
  107. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
    View in: PubMed
    Score: 0.012
  108. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956.
    View in: PubMed
    Score: 0.012
  109. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
    View in: PubMed
    Score: 0.012
  110. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405.
    View in: PubMed
    Score: 0.012
  111. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.012
  112. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8.
    View in: PubMed
    Score: 0.012
  113. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
    View in: PubMed
    Score: 0.011
  114. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
    View in: PubMed
    Score: 0.011
  115. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
    View in: PubMed
    Score: 0.011
  116. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
    View in: PubMed
    Score: 0.011
  117. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
    View in: PubMed
    Score: 0.011
  118. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91.
    View in: PubMed
    Score: 0.011
  119. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.011
  120. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
    View in: PubMed
    Score: 0.011
  121. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
    View in: PubMed
    Score: 0.011
  122. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
    View in: PubMed
    Score: 0.011
  123. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
    View in: PubMed
    Score: 0.011
  124. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73.
    View in: PubMed
    Score: 0.011
  125. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
    View in: PubMed
    Score: 0.011
  126. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.011
  127. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
    View in: PubMed
    Score: 0.010
  128. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.
    View in: PubMed
    Score: 0.010
  129. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2.
    View in: PubMed
    Score: 0.010
  130. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.010
  131. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65.
    View in: PubMed
    Score: 0.010
  132. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
    View in: PubMed
    Score: 0.010
  133. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.
    View in: PubMed
    Score: 0.010
  134. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306.
    View in: PubMed
    Score: 0.010
  135. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
    View in: PubMed
    Score: 0.010
  136. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
    View in: PubMed
    Score: 0.010
  137. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8.
    View in: PubMed
    Score: 0.010
  138. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.009
  139. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
    View in: PubMed
    Score: 0.009
  140. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.009
  141. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401.
    View in: PubMed
    Score: 0.009
  142. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.009
  143. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
    View in: PubMed
    Score: 0.009
  144. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
    View in: PubMed
    Score: 0.009
  145. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31.
    View in: PubMed
    Score: 0.009
  146. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
    View in: PubMed
    Score: 0.009
  147. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503.
    View in: PubMed
    Score: 0.009
  148. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
    View in: PubMed
    Score: 0.009
  149. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16.
    View in: PubMed
    Score: 0.009
  150. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44.
    View in: PubMed
    Score: 0.009
  151. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.
    View in: PubMed
    Score: 0.009
  152. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203.
    View in: PubMed
    Score: 0.009
  153. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
    View in: PubMed
    Score: 0.009
  154. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
    View in: PubMed
    Score: 0.009
  155. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.009
  156. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12.
    View in: PubMed
    Score: 0.008
  157. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45.
    View in: PubMed
    Score: 0.008
  158. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
    View in: PubMed
    Score: 0.008
  159. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
    View in: PubMed
    Score: 0.008
  160. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8.
    View in: PubMed
    Score: 0.008
  161. Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9.
    View in: PubMed
    Score: 0.008
  162. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92.
    View in: PubMed
    Score: 0.008
  163. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
    View in: PubMed
    Score: 0.008
  164. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410.
    View in: PubMed
    Score: 0.008
  165. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
    View in: PubMed
    Score: 0.008
  166. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.008
  167. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901.
    View in: PubMed
    Score: 0.008
  168. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93.
    View in: PubMed
    Score: 0.008
  169. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.
    View in: PubMed
    Score: 0.008
  170. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.008
  171. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
    View in: PubMed
    Score: 0.008
  172. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17; 57(20):2037-114.
    View in: PubMed
    Score: 0.007
  173. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506.
    View in: PubMed
    Score: 0.007
  174. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45.
    View in: PubMed
    Score: 0.007
  175. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
    View in: PubMed
    Score: 0.007
  176. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
    View in: PubMed
    Score: 0.007
  177. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
    View in: PubMed
    Score: 0.007
  178. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
    View in: PubMed
    Score: 0.007
  179. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8.
    View in: PubMed
    Score: 0.007
  180. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41.
    View in: PubMed
    Score: 0.007
  181. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.007
  182. Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). Diabetes Care. 2010 Dec; 33(12):2586-91.
    View in: PubMed
    Score: 0.007
  183. Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7.
    View in: PubMed
    Score: 0.007
  184. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
    View in: PubMed
    Score: 0.007
  185. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
    View in: PubMed
    Score: 0.007
  186. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.007
  187. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33.
    View in: PubMed
    Score: 0.007
  188. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60.
    View in: PubMed
    Score: 0.007
  189. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31.
    View in: PubMed
    Score: 0.007
  190. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103.
    View in: PubMed
    Score: 0.007
  191. Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism. 2010 Mar; 59(3):385-9.
    View in: PubMed
    Score: 0.007
  192. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.007
  193. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
    View in: PubMed
    Score: 0.007
  194. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010 Oct 29; 144(3):383-8.
    View in: PubMed
    Score: 0.007
  195. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.006
  196. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010 Jul 23; 142(3):279-87.
    View in: PubMed
    Score: 0.006
  197. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8.
    View in: PubMed
    Score: 0.006
  198. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.006
  199. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
    View in: PubMed
    Score: 0.006
  200. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009 Sep 11; 137(1):1-8.
    View in: PubMed
    Score: 0.006
  201. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6.
    View in: PubMed
    Score: 0.006
  202. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
    View in: PubMed
    Score: 0.006
  203. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
    View in: PubMed
    Score: 0.006
  204. Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008 Mar; 10(3):234-8.
    View in: PubMed
    Score: 0.006
  205. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
    View in: PubMed
    Score: 0.006
  206. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
    View in: PubMed
    Score: 0.006
  207. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.006
  208. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.006
  209. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.006
  210. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.006
  211. The ADVANCE trial: further PROGRESS with HOPE. J Hum Hypertens. 2007 Dec; 21(12):911-3.
    View in: PubMed
    Score: 0.006
  212. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
    View in: PubMed
    Score: 0.006
  213. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.006
  214. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305.
    View in: PubMed
    Score: 0.006
  215. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5.
    View in: PubMed
    Score: 0.006
  216. beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17.
    View in: PubMed
    Score: 0.006
  217. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
    View in: PubMed
    Score: 0.006
  218. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
    View in: PubMed
    Score: 0.006
  219. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007 Feb; 38(2):441-50.
    View in: PubMed
    Score: 0.006
  220. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
    View in: PubMed
    Score: 0.006
  221. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
    View in: PubMed
    Score: 0.006
  222. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8.
    View in: PubMed
    Score: 0.005
  223. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
    View in: PubMed
    Score: 0.005
  224. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
    View in: PubMed
    Score: 0.005
  225. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
    View in: PubMed
    Score: 0.005
  226. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84.
    View in: PubMed
    Score: 0.005
  227. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
    View in: PubMed
    Score: 0.005
  228. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
    View in: PubMed
    Score: 0.005
  229. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63.
    View in: PubMed
    Score: 0.005
  230. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804.
    View in: PubMed
    Score: 0.005
  231. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8.
    View in: PubMed
    Score: 0.005
  232. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80.
    View in: PubMed
    Score: 0.005
  233. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.005
  234. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.004
  235. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
    View in: PubMed
    Score: 0.004
  236. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.004
  237. Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer. 1983 Aug 01; 52(3):493-7.
    View in: PubMed
    Score: 0.004
  238. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.004
  239. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.004
  240. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77.
    View in: PubMed
    Score: 0.004
  241. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
    View in: PubMed
    Score: 0.004
  242. Disopyramide-associated liver dysfunction. Mayo Clin Proc. 1983 Apr; 58(4):265-7.
    View in: PubMed
    Score: 0.004
  243. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.004
  244. Psychogenic vertigo: a review. Postgrad Med. 1981 Nov; 70(5):69-71, 74, 77.
    View in: PubMed
    Score: 0.004
  245. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.004
  246. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
    View in: PubMed
    Score: 0.003
  247. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990 May; 30(5):468-75.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.